What is NDC 62064-381?

62064-381 is the product NDC for Egrifta Wr (tesamorelin) kit, listed with the FDA by Theratechnologies Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Theratechnologies Inc., NDC labeler code 62064. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Egrifta Wr?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Egrifta Wr NDC 62064-381 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62064-381Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62064-0381Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62064-381-04	62064038104	1 KIT in 1 BOX (62064-381-04) * 1.3 mL in 1 VIAL (62064-371-01) * 30 mL in 1 BOTTLEMarketed from Jul 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Egrifta Wr
Generic name (nonproprietary): tesamorelin
Dosage form: Kit
Route: Subcutaneous
Labeler: Theratechnologies Inc.NDC labeler code 62064
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 022505
Marketing start: Jul 15, 2025
Listing expires: Dec 31, 2027
Identifiers: Product ID 62064-381_285bfbe0-2839-441c-9d4d-990b6f413e7bSPL ID 285bfbe0-2839-441c-9d4d-990b6f413e7bSPL set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75RxCUI 2719314, 2719316

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N462064038104 followed by a unit qualifier and the quantity

Package 62064-0381-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 29, 2026.

Indications (excerpt from the label)

EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA WR has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR. EGRIFTA WR is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodys…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62064-381

What is NDC 62064-381?: 62064-381 is the product NDC for Egrifta Wr (tesamorelin) kit, listed with the FDA by Theratechnologies Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Egrifta Wr (Tesamorelin).
Who is the labeler?: Theratechnologies Inc., NDC labeler code 62064. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Egrifta Wr?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under BLA 022505

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 022505
Product	Strength	Form · route	Labeler	Product NDC
Egrifta Svtesamorelin	—	KitSubcutaneous	Theratechnologies Inc.	62064-241

Egrifta Wr (Tesamorelin) NDC 62064-381